GlobeNewswire
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“First Generation”), a company affiliated with the Chairman of the Board of Directors of Acerus1, to increase its existing secured loan facility (the “Loan Facility”) from US$30.845 million to US$35.845 million. This increase will be made available to the Company by way